{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKI&page=7", "query": { "intervention": "TKI", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 232, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKI&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKI&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T07:30:59.867Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04370509", "title": "Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma", "Recurrent Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Axitinib (VEGF-TKI)", "type": "DRUG" }, { "name": "Cytoreductive Nephrectomy (CN)", "type": "PROCEDURE" }, { "name": "Metastasectomy (MET)", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-02-09", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370509" }, { "nct_id": "NCT02511106", "title": "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IB-IIIA Non-small Cell Lung Carcinoma" ], "interventions": [ { "name": "AZD9291 80 mg/40 mg", "type": "DRUG" }, { "name": "Placebo AZD9291 80 mg/40 mg", "type": "DRUG" }, { "name": "Open-label AZD9291 80 mg/40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 682, "start_date": "2015-10-21", "completion_date": "2029-01-31", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 23, "location_summary": "Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511106" }, { "nct_id": "NCT01223027", "title": "Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 564, "start_date": "2011-03", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 34, "location_summary": "Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01223027" }, { "nct_id": "NCT05131646", "title": "Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "CLS-AX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 15, "start_date": "2021-10-08", "completion_date": "2023-01-05", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Mountain View, California • Sacramento, California + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Mountain View", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Hagerstown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05131646" }, { "nct_id": "NCT03515837", "title": "Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "saline solution", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 492, "start_date": "2018-06-29", "completion_date": "2023-10-02", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 19, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515837" }, { "nct_id": "NCT02771626", "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma (ccRCC)", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2016-08-01", "completion_date": "2020-04-24", "has_results": true, "last_update_posted_date": "2023-03-17", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771626" }, { "nct_id": "NCT03797391", "title": "A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Neoplasm Metastasis", "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "EMB-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2018-12-13", "completion_date": "2026-01-15", "has_results": false, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Canton, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797391" }, { "nct_id": "NCT05068024", "title": "A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "FWD1509 MsOH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forward Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-08-23", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 2, "location_summary": "Canton, Ohio • Houston, Texas", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05068024" }, { "nct_id": "NCT05695417", "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-proliferative Diabetic Retinopathy" ], "interventions": [ { "name": "OTX-TKI", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocular Therapeutix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-01-15", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-12-08", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Lemont", "state": "Illinois" }, { "city": "Hagerstown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695417" }, { "nct_id": "NCT03797326", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Triple Negative Breast Cancer", "Ovarian Cancer", "Gastric Cancer", "Colorectal Cancer", "Glioblastoma", "Biliary Tract Cancers", "Pancreatic Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 611, "start_date": "2019-02-12", "completion_date": "2024-10-28", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-11-02T07:30:59.867Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797326" } ] }